Puma Biotechnology (PBYI) Payables (2011 - 2026)

Puma Biotechnology (PBYI) has 16 years of Payables data on file, last reported at $8.2 million in Q1 2026.

• Quarterly Payables rose 35.51% year-over-year to $8.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.2 million (up 35.51% YoY) and the FY2025 annual result came in at $5.1 million, down 8.22% from the prior year.
• Payables rose to $8.2 million in Q1 2026, from $5.1 million in the prior quarter.
• In the past five years, Payables ranged from a high of $14.9 million in Q3 2022 to a low of $5.1 million in Q4 2025.
• A 5-year average of $7.9 million and a median of $7.4 million in 2022 frame the typical range for Payables.
• Annual changes were most pronounced in 2023 — Payables tumbled 66.09% — and 2024, when it jumped 73.19%.
• Tracing PBYI's Payables over 5 years: stood at $6.4 million in 2022, then increased by 6.97% to $6.9 million in 2023, then fell by 20.03% to $5.5 million in 2024, then slipped by 8.22% to $5.1 million in 2025, then jumped by 61.51% to $8.2 million in 2026.
• The last three Payables figures came in at $8.2 million (Q1 2026), $5.1 million (Q4 2025), and $6.4 million (Q3 2025), per Business Quant data.